Targeting HER2-positive breast cancer: advances and future directions. [Review] 

 -  2022 
<br/><br/> The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug - the monoclonal antibody trastuzumab - almost 25 years ago. Since then, progress has been swift and the impressive clinical activity across multiple trials with monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates that target HER2 has spawned extensive efforts to develop newer platforms and more targeted therapies. This Review discusses the current standards of care for HER2-positive breast cancer, mechanisms of resistance to HER2-targeted therapy and new therapeutic approaches and agents, including strategies to harness the immune system. Copyright © 2022. Springer Nature Limited. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>1474-1776 
<br/><br/><label>Standard No.: </label>10.1038/s41573-022-00579-0 [doi] 10.1038/s41573-022-00579-0 [pii] PMC9640784 [pmc] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>IN PROCESS -- NOT YET INDEXED
<br/><br/><label>Index Terms--Occupation: </label><br/>Associate Dean for Research Development<br/>MedStar Health
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article<br/>Review